Delivery Order SPE2DB20D9214-SPE2DB25FD4WM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,169.59 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for the supply of 4,566,561,052 units of the prescription drug Xtandi 40 mg tablet, with a completion date of November 27, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of the drug Xtandi 80 mg tablets and has an ultimate completion date of August 27, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xtandi 80 mg tablets. This delivery order is part of a larger single-award indefinite delivery contract (IDC) between the DLA and DMS Pharmaceutical Group, valued up to $499,999,999, that runs through December 31, 2025. The IDC...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,792.31 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location with completion expected by July 24, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete in the open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The place of performance is located in Park Ridge, Illinois, where the vendor...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- This is a $4,169.59 firm fixed-price delivery order awarded by the Defense Logistics Agency's Medical Supply Chain group to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The order is for 120 tablets of the prescription drug Xtandi 40mg, with an ultimate completion date of March 20, 2024. DMS Pharmaceutical Group holds a broader indefinite delivery contract (SPE2DB) with the Defense Logistics Agency valued at up to $4,999,999 through 2025, which...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,017.54 on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award was issued under a firm fixed-price contract type with no set-aside designation, reflecting the company's competitive standing in federal procurement markets. The funding agency is the Defense Logistics Agency's Medical Supply Chain division, and...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4WMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city. This delivery order operates under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at approximately $500 million and valid through November 2026. The IDC, designated SPE2DB, enables DLA to issue firm fixed-price delivery orders for pharmaceutical products supporting military health facilities worldwide. Xtandi, an oncology medication, aligns with DMS Pharmaceutical Group's established portfolio of specialty pharmaceutical products including prescription medications, biologics, and medical consumables. As a established federal contractor with a robust history of pharmaceutical supply to defense healthcare systems since its SAM.gov registration in 2001, DMS Pharmaceutical Group has consistently leveraged its woman-owned small business status to compete effectively in federal procurement markets.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 7/22/25 |